Lincoln Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2014 • Pharmaceutical: 78.8% • Chemical: 21.2%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Company has a healthy return on capital (ROCE) of 20.6%
- Company has consistently been profitable over the last 5 years
- Latest quarter profit grew 30.9% YoY, showing strong momentum
- Company generates healthy free cash flow
- Company has a consistent dividend-paying track record
CONS
- Operating margins have contracted to 15.5% from 21.2%
- Company has delivered a poor profit growth of 9.9% over past five years
- Though reporting repeated profits, the company pays out little dividend (4.4%)
- Expensive relative to growth - PEG of 2.2
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| LINCOLN | 625.05 | 12.98 | 1251.96 | 0.29 | 36.23 | 30.93 | 177.28 | 15.07 | 17.55 | 15.47 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 136 | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 | |
| 115 | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 | 138 | 143 | 162 | 154 | |
| Operating Profit | 21 | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 23 |
| OPM % | 15.28% | 19.97% | 20.25% | 12.90% | 15.43% | 17.60% | 16.14% | 15.89% | 15.45% | 15.56% | 14.18% | 13.27% | 13.14% |
| 8 | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 | 7 | 15 | -4 | 24 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before Tax | 25 | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 |
| Tax % | 25.27% | 24.98% | 25.64% | 16.29% | 19.71% | 24.30% | 27.58% | 28.74% | 21.79% | 30.65% | 17.63% | 30.36% | 23.80% |
| Net Profit | 0 | 0 | 0 | 0 | 24 | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 |
| 9.49 | 13.81 | 14.00 | 9.28 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 400 | 360 | 361 | 366 | 386 | 424 | 472 | 510 | 581 | 623 | 694 | |
| 360 | 314 | 308 | 299 | 321 | 337 | 377 | 421 | 481 | 522 | 597 | |
| Operating Profit | 41 | 47 | 52 | 67 | 66 | 87 | 95 | 89 | 100 | 101 | 97 |
| OPM % | 10.13% | 12.97% | 14.51% | 18.36% | 16.96% | 20.55% | 20.22% | 17.48% | 17.21% | 16.29% | 13.99% |
| 7 | 3 | 5 | 6 | 11 | 6 | 10 | 22 | 34 | 22 | 42 | |
| Interest | 10 | 7 | 5 | 4 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Depreciation | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | 11 | 13 | 15 |
| Profit before Tax | 33 | 37 | 46 | 62 | 67 | 84 | 96 | 100 | 122 | 109 | 128 |
| Tax % | 28.02% | 24.64% | 25.08% | 21.63% | 23.45% | 25.65% | 27.71% | 27.45% | 23.67% | 24.58% | 24.52% |
| Net Profit | 24 | 28 | 35 | 49 | 51 | 62 | 69 | 73 | 93 | 82 | 96 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.08 | 34.63 | 36.40 | 46.58 | 41.11 | — |
| Dividend Payout % | 6.89% | 8.53% | 8.66% | 6.16% | 5.83% | 4.83% | 4.33% | 4.12% | 3.86% | 4.38% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 9%
- 5 Years:
- 10%
- 3 Years:
- 10%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 19%
- 5 Years:
- 10%
- 3 Years:
- 6%
STOCK PRICE CAGR
- 10 Years:
- 10%
- 5 Years:
- 9%
- 3 Years:
- 8%
- 1 Year:
- 12%
RETURN ON EQUITY
- 10 Years:
- 17%
- 5 Years:
- 16%
- 3 Years:
- 15%
- Last Year:
- 13%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| 117 | 172 | 204 | 249 | 293 | 346 | 413 | 482 | 573 | 652 | |
| 79 | 69 | 65 | 38 | 9 | 5 | 7 | 7 | 5 | 5 | |
| Trade Payables | 30 | 32 | 43 | 44 | 51 | 57 | 72 | 51 | 72 | 85 |
| 32 | 30 | 30 | 47 | 63 | 59 | 43 | 76 | 55 | 60 | |
| Total Liabilities | 275 | 324 | 363 | 399 | 437 | 487 | 555 | 637 | 725 | 822 |
| 98 | 103 | 117 | 121 | 123 | 111 | 132 | 151 | 179 | 182 | |
| Capital Work in Progress | 3 | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 4 |
| 0 | 10 | 11 | 18 | 34 | 81 | 97 | 91 | 139 | 174 | |
| 27 | 37 | 45 | 36 | 47 | 47 | 73 | 70 | 77 | 79 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 162 | 166 | |
| Cash & Bank | 13 | 12 | 15 | 8 | 15 | 14 | 19 | 34 | 14 | 22 |
| 133 | 155 | 175 | 214 | 218 | 234 | 218 | 284 | 151 | 194 | |
| Total Assets | 275 | 324 | 363 | 399 | 437 | 487 | 555 | 637 | 725 | 822 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 52 | 35 | 36 | 70 | 90 | 89 | 100 | 69 | 63 | 93 | |
| Cash from Investing | -42 | -25 | -12 | -18 | -31 | -64 | -78 | -37 | -57 | -79 |
| Cash from Financing | -3 | 0 | -11 | -36 | -38 | -6 | -3 | -5 | -5 | -6 |
| -0 | -0 | 3 | -1 | 7 | -1 | -5 | -2 | 1 | 8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-07 - Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for Notice of 32nd Annual General Meeting.
2026-09-05 - Lincoln Pharmaceuticals Limited has informed the Exchange Intimation regarding dispatch of physical communication to the Shareholders who have not registered their email address. ''.
2026-09-05 - Lincoln Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026.
2026-08-29 - Lincoln Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Sep-2026.
2026-08-26 - Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication regarding the 32nd Annual General Meeting of the Company to be held on Wednesday, September 30, 2026.
2026-08-14 - Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-13 - Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-06 - Lincoln Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
2026-06-24 - Lincoln Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
News
Recent coverage and analyst commentary for LINCOLN
Loading news…
AI Stock Analyst
Lincoln Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account